{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-093920","form_type":"8-K","ticker":"DNTH","cik":"0001690585","company_name":"Dianthus Therapeutics, Inc. /DE/","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.125718+00:00","generated_at":"2026-05-31T11:02:57.430418+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Dianthus reports Q2 net loss $17.6M; cash $360.7M funds pipeline into 2H'27","bullets":["Net loss $17.6M ($0.51/share) vs $11.1M ($12.73/share) in Q2 2023.","Cash, equivalents & short-term investments $360.7M as of June 30, 2024, projected runway into 2H'27.","Phase 2 MaGic trial in gMG ongoing; top-line results expected 2H'25.","IND cleared for Phase 2 MoMeNtum trial in MMN; top-line results anticipated 2H'26.","Alison Lawton appointed Chair of Board, effective July 1, 2024, succeeding Lonnie Moulder."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-093920","json":"https://secwatch.observer/filing/0000950170-24-093920.json","markdown":"https://secwatch.observer/filing/0000950170-24-093920.md","text":"https://secwatch.observer/filing/0000950170-24-093920.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690585/000095017024093920/0000950170-24-093920-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690585/000095017024093920/dnth-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:02:57.430418+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}